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Psychoactive substance use  
affects the functioning of the brain  
and leads to impaired driving
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A growing concern
There is growing concern around the world 
about drug use and road safety. Drinking 
alcohol and driving is a well studied risk 
factor for road traffic crashes, injuries and 
deaths but drug-induced impairment of 
driving is causing increasing concern in 
many countries around the world. For many 
years there have been several gaps in our 
knowledge, particularly about the global 
extent of the problem, the relationship 
between drug concentrations and crash 
risk, appropriate threshold limits in blood, 
legislation and enforcement of effective 
measures to prevent drug-driving. However, 
these knowledge gaps are progressively 
being filled by a growing body of evidence on 
drug use and road safety, including effective 
ways to reduce drug-induced road traffic 
crashes and injuries (1-8).
The purpose of the document is to provide 
up-to-date information on drug use and road 
safety to support informed decisions on road 
safety and drug policies in WHO Member 
States. This document focuses on drug-
driving and not on drink-driving. Drawing 
on the growth in knowledge in this area over 
recent decades, the document describes 
the impact of drug use on road safety and 
suggests what can be done to reduce drug-
related crashes, injuries and deaths on the 
roads. Three categories of psychoactive 
drug are relevant to the risk of road traffic 
injury (Figure 1).
For the purpose of this document the term “drug” is used as an 
equivalent of “psychoactive drug”, which refers to a substance that 
has the ability to affect mental processes such as an individual’s 
consciousness, mood or thinking. The term “drug” in this document 
does not include alcohol and nicotine which are covered by the term 
“psychoactive substance”. 
Figure 1
Psychoactive drugs relevant to road traffic injury risk
New psychoactive substances (e.g. 
synthetic cannabinoids, synthetic 
cathinones) are synthesized and 
consumed for nonmedical purposes with 
expectation of effects of well-known 
illicit drugs.
Illicit drugs (e.g. cocaine, heroin, 
methamphetamine, cannabis) are under 
international control and are largely 
produced and consumed for nonmedical 
purposes. 
Prescription drugs  (e.g. 
antidepressants, benzodiazepines, 
opioid analgesics) can be bought 
legally or prescribed by a doctor 
for the management of acute or 
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How do psychoactive drugs 
impair driving?
Psychoactive drugs affect the functioning 
of the brain and may lead to impaired 
driving (e.g. by delaying reaction time and 
information processing, reducing perceptual-
motor coordination and motor performance, 
as well as attention, road tracking and vehicle 
control). The ways in which different drugs 
affect brain functioning are summarized in 
Table 1. 












Cocaine — — — —
Amphetamines — —













cathinones — — — —
Source: Based upon reference (9).
: the drug has an impairment effect.
–: the drug has no impairment effect.
a Methylenedioxymethamphetamine.
Table 1
Ways in which different drugs affect brain functioning
 3 A policy brief
Drug Crash severity Best estimate of relative risk 





Fatal 5.17 (2.56, 10.42)
Injury 6.19 (3.46, 11.06)
Property damage 8.67 (3.23, 23.32)
Analgesics Injury 1.02 (0.89, 1.16)
Anti-asthmatics Injury 1.31 (1.07, 1.59)
Anti-depressives Injury 1.35 (1.11, 1.65)
Property damage 1.28 (0.90, 1.80)
Anti-histamines Injury 1.12 (1.02, 1.22)
Benzodiazepines
 
Fatal 2.30 (1.59, 3.32)
Injury 1.17 (1.08, 1.28)
Property damage 1.35 (1.04, 1.76)
Cannabis
 
Fatal 1.26 (0.88, 1.81)
Injury 1.10 (0.88, 1.39)




Fatal 2.96 (1.18, 7.38)
Injury 1.66 (0.91, 3.02)
Property damage 1.44 (0.93, 2.23)
Opiates Fatal 1.68 (1.01, 2.81)
Injury 1.91 (1.48, 2.45)
Property damage 4.76 (2.10, 10.80)
Penicillin Injury 1.12 (0.91, 1.39)
Zopiclone
 
Fatal 2.60 (0.89, 7.56)
Injury 1.42 (0.87, 2.31)
Property damage 4.00 (1.31, 12.21)
Source: Based upon reference (6).
Notes: Estimates shown in bold are statistically significant at the 5% level.
Table 2
Summary estimates of relative risk of road traffic crash associated with the use of various drugs
The risk of getting involved in a road traffic 
crash is increased to varying degrees 
depending on the psychoactive drug used 
(Table 2). For example, the risk of a fatal 
crash occurring among those who have used 
amphetamines is about five times higher 
than among persons who have not used 
them. 
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Epidemiology of drug use and 
road traffic injuries
Surveys and laboratory tests from various 
countries show that psychoactive drug use 
is reported frequently by drivers or detected 
in the biological fluids of injured or killed 
drivers. For instance: 
• Roadside surveys show that the prevalence 
of any psychoactive drug among drivers 
ranges from 3.9% to 20.0% (10, 11). 
• Population surveys show that self-reported 
driving after using psychoactive drugs 
(mostly cannabis) varies in different 
countries between 3.8% and 29.9% (12, 13).
• Prevalence of drug use (such as 
amphetamines, benzodiazepines, cannabis 
and cocaine) among fatally injured persons 
in a road traffic crash ranges from 8.8% to 
33.5% (10, 14).
In 2013, illicit drug use was estimated to be 
responsible for just over 39 600 road traffic 
deaths worldwide (15). Amphetamine use 
was estimated to cause around  half of these 
deaths while cannabis was estimated to 
cause one fifth of them (Figure 2). Although 
there were more deaths due to drink-driving 
worldwide in the same year (just over 
188 000), the risk of death from drug-driving 
remains high.
Figure 2
Proportion of drug-related road traffic deaths
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Prevention and early 
interventions
Measures that need to be in place and 
implemented in a comprehensive manner 
cover five essential areas: legislation, 
testing, enforcement, awareness-raising, 
and counselling and treatment.
Establishing drug-driving laws 
and regulations
The type of legal framework varies 
according to the social, legal and economic 
characteristics of a particular jurisdiction, 
as well as the historical context of the 
development of laws designed to improve 
road user safety. 
• Zero tolerance laws make it unlawful to 
drive with any amount of specified drugs 
in the body. 
• Impairment laws make it unlawful 
to drive when the ability to drive has 
become impaired following drug use, often 
described as being “under the influence” 
or in similar terms.
• Per se laws make it unlawful to drive with 
amounts of specified drugs that exceed 
the maximum set concentration. The 
specific link between drug concentration, 
impairment and the risk of a crash still 
needs more research. To date, a few 
countries, including the United Kingdom, 
have adopted per se laws (Box 1). 
A total of 159 countries around the world 
have national legislation prohibiting drug-
driving but most of these laws do not define 
what is considered to be a “drug”, nor do 
they specify a threshold (7). It will be difficult 
to enforce drug-driving laws in countries that 
have neither defined what is considered to be 
a “drug” nor specified a threshold.
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EXCERPTS FROM ROAD TRAFFIC ACT 1988


















Specified controlled drugs and specified limits in England and 
Wales based on the Drug-Driving (specified limits) (England and 
Wales) Regulations 2014 and the Drug-Driving (specified limits) 
(England and Wales) Amendments regulations 2015  
Section 4. Driving, or being in 
charge, when under influence of 
drink or drugs.
(1) A person who, when driving or attempting to 
drive a mechanically propelled vehicle on a road 
or other public place, is unfit to drive through 
drink or drugs is guilty of an offence.
(2) Without prejudice to subsection (1) above, 
a person who, when in charge of a mechanically 
propelled vehicle which is on a road or other 
public place, is unfit to drive through drink or 
drugs is guilty of an offence.
(…)
Section 5A. Driving or being in 
charge of a motor vehicle with 
concentration of specified controlled 
drug above specified limit
(1) This section applies where a person (“D”)—
(a) drives or attempts to drive a motor 
vehicle on a road or other public place, or
(b) is in charge of a motor vehicle on a road 
or other public place, and there is in D’s body 
a specified controlled drug. 
(2) D is guilty of an offence if the proportion 
of the drug in D’s blood or urine exceeds the 
specified limit for that drug.
(…) 
Box 1
Drug-driving legislation in the United Kingdom
In 2012, the government of the United Kingdom announced a new offence in relation to driving with specific controlled drugs 
in the body above the limit specified in regulations. The Crime and Courts Act inserted a new section 5A in the Road Traffic 
Act 1988 (16,17). Thus, on 2 March 2015, new regulations came into force in England and Wales, addressing eight general 
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Testing for drug use
Testing for the presence of a drug in the 
body fluid ascertains whether a particular 
drug is present and, in some cases, at what 
concentration. An important factor is whether 
the legal framework allows random testing 
or requires a suspicion of drug impairment 
before a drug test can be administered. Oral 
fluid sampling is relatively non-invasive, and 
can be carried out anywhere and without 
requiring medical or specialist qualifications.
Testing and/or detecting drugs can be done 
at the roadside (Box 2) and in hospital 
emergency rooms or other settings to 
determine the extent of drug use among 
drivers and other road users. It is important 
to detect and monitor the trend in the use 
of drugs among drivers and other road 
users continuously to determine the scale 
of the problem and to develop appropriate 
measures. Where a threshold concentration 
has been specified in legislation, in order for 
the legislation to work, enforcement officers 
must be trained to collect samples of bodily 
fluid for testing. For drugs that as yet 
have no set threshold, enforcement officers 
must be trained to recognize clinical 
signs and symptoms of drug use, assess 
impairment, and take samples to determine 
the type and concentration of substance 
present. The type and concentration of 
substance present can also be tested on 
injured persons attending hospitals or 
emergency rooms.
Box 2
Roadside drug-use testing in Australia
Australia has a national road safety strategy. However, each of the six states and two territories of Australia is responsible for 
road safety policy, legislation and enforcement within its jurisdiction (18–20). Each of the eight jurisdictions in Australia has a 
roadside drug-testing programme. The State of Victoria was the first jurisdiction to introduce random roadside drug-testing 
just over a decade ago, with the other jurisdictions progressively introducing similar programmes over the following seven 
years.
The roadside testing process for illicit drugs in Victoria involves a five-step process: 
Step 1: Vehicle intercept
Step 2: Roadside preliminary oral fluid sample
Step 3: Second oral fluid sample screening
Step 4: Laboratory confirmation analysis
Step 5: Prosecution if the person has a previous offence
If there is no previous offence and the 
sample is positive, the case is dealt with by 
a penalty notice issued by the police with a 
fine and suspension of the driving licence. 
Different devices may be used for the 
roadside preliminary test. They give 
positive or negative readings in three 
minutes. Over 300 000 tests were 
conducted in Victoria between 2005 
and 2014. The prevalence of positive 
test results went down between 2005 
and 2010 but has begun to rise again. 
Methamphetamine accounted for 85% of 
positive drug tests, cannabis for 32%, and 
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Enforcing drug-driving laws
It is critical that a drug-driving law is 
visibly and regularly enforced. In addition, 
appropriate penalties should be imposed to 
support compliance with the requirements of 
Box 3
Enforcing drug-driving laws in Spain
Spanish drug-driving laws have a dual approach: drug driving is considered as both an administrative infringement (Law 
6/2014) (21) and a criminal offence (Organic Law 5/2010) (22). Drug-driving as an administrative infringement is based on 
a zero tolerance system where the person driving with any amount of drugs (except prescribed medicines for therapeutic 
purposes) is punished by a fine (1000 Euros) and demerit points (6 points) (Law 6/2014). Drug-driving as a criminal offence is 
based on the impairment of the driver due to drugs as shown by impairment signs, where the law punishes the person driving 
under the influence of drugs by imprisonment (3–6 months), or a fine, or community service (31–90 days) and by driving 
disqualification (for 1–4 years) (Organic Law 5/2010). The penalties imposed for drug-driving are either those prescribed 
for the administrative infringement or those relating to the criminal offence; the penalties relating to both laws cannot be 
simultaneously applied for the same infraction.
If stopped randomly at a checkpoint, or if involved in a road traffic crash or if committing another (road traffic) infraction, drivers 
are subjected to a drug test and are obliged to provide a saliva sample. The drivers are first submitted to a roadside screening 
test for drugs using oral fluid. If the result is positive, a second mandatory evidential oral fluid sample is sent to a toxicology 
laboratory. The driver has the right to request a blood sample. Surveys conducted among drivers subjected to roadside drug 
screening  in Spain shows a decrease in prevalence of psychoactive drugs from 6.9% in 2008 to 4.9% in 2013 (23).
the law (Box 3). Without visible enforcement 
and swift penalties, a drug-driving law has 
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Raising awareness of drug-driving
Raising awareness of drug-driving and its 
impact on road safety – including deaths, 
injuries, property damage and harm to 
other road users – among the general public 
and policy-makers can reduce drug-driving 
and create a climate in which legislation 
and enforcement will be supported 
(Boxes 4 and 5). 
Box 4
The United Kingdom’s THINK! drug-driving campaign 
A new drug-driving law came into force on 2 March 2015 in England and Wales. The law makes it an offence to drive with any of 
the 17 controlled drugs above a specified level in the blood. A THINK! drug-driving campaign was designed to inform road users 
and promote adherence to the new law (24).
The specific objective of the campaign was to raise awareness of the 
new law among all adults and to challenge and deter young male drivers 
between 17 and 34 years of age from driving under the influence of drugs. 
The messages developed focused on the legal consequences of drug-
driving, both illicit drugs and medical drugs, and invited audiences to get 
more information from health-care professionals. The campaign included 
a variety of promotional materials and activities aimed at reaching out to 
the target audience in as many ways as possible. Among these there were 
a website, television and radio adverts, printed materials as well as pre-
campaign activities with health-care professionals and police to ensure that 
they were aware and prepared before messages were communicated to the 
general public. The campaign attracted the attention of news media which 
contributed to giving visibility to the topic. The campaign materials were 
disseminated for six weeks. 
Evaluation of the media campaign targeting 17–34-year-old males found 
that campaign recognition was good: 52% of the target audience recognised 
at least one of the advertisements and 26% agreed they had “seen or heard 
anything recently about changes to drug-driving legislation”. Awareness of 
the personal consequences of drug-driving also increased significantly from 






















Teen drugged driving: an activity guide for parents, coalitions and community groups
The Teen drugged driving toolkit, released in 2011 in the USA, was created to provide coalitions, prevention groups and parent 
organizations with (25): 
• facts on the danger and extent of teen and young adult drug-driving;
• activities for effective prevention; and 
• resources to further assist in prevention activities.
Evidence shows that, because teens are the least experienced drivers as a group, they have a higher risk of being involved in a 
road traffic crash compared with more experienced drivers. When this lack of experience is combined with the use of marijuana 
or other substances – which alter perception, cognition, reaction time and other faculties – the results can be tragic. The 
included activities were designed to raise awareness about drug-driving, to give parents and community leaders tips and advice 
on identifying the risks of drug-driving, to encourage local media to raise awareness of the dangers of drug-driving, and to 
educate parents and teens about the issue. The first activity consisted of a programme guide to host a drug-driving prevention 
night (including discussion guide and media pitch materials). The second activity was the development of guidelines for a 
drug-driving poster contest (including promotional language, discussion guide and sample teen posters). This toolkit has been 
distributed to more than 600 Drug-Free Community programmes in all 50 states of the USA, and has been utilized by youth-
serving non-profit organizations – including Students Against Destructive Decisions (SADD) and National Organizations for 
Youth Safety (NOYS).
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Box 6
Treatment of drug-impaired drivers in Sweden 
The Swedish programme Samverkan mot alkohol och droger i trafiken (SMADIT) (United action against alcohol and drugs on 
the roads) is a cooperative effort of several authorities: the Swedish Transport Administration, the Swedish Police, the Swedish 
Coast Guard, Swedish Customs, local authorities, county councils, the Swedish Transport Agency, the Prison and Probation 
Service, and the county administrative boards. People reported for drink-driving and/or drug-driving on the road or at sea are 
offered professional help promptly. The aim is to reduce impaired driving and offer options for alcohol- and drug-impaired 
drivers to handle their problems. All local authorities in Sweden work according to SMADIT although the programme is applied 
in different ways in different parts of the country.
In Örebro county, in the southern central part of Sweden, SMADIT is being applied and persons caught by police under suspicion 
of drink-driving, drug-driving, minor narcotics offences or doping crime are offered a motivational interview with staff of the 
Addiction Centre as well as further support from the centre, the social services or the probation services. An evaluation of 
SMADIT-Örebro sought to determine if accepting further support had any impact on recidivism in drink- and drug-driving and 
other crimes (26). The methods comprised a retrospective register study of 840 individuals and a prospective interview study 
of 172 persons who experienced SMADIT-Örebro. Data were collected during 2013–2015. According to preliminary results of the 
register study, it could not be shown that undergoing the SMADIT-Örebro programme resulted in fewer offences due to driving 
under the influence. However, qualitative data suggest many participants felt positively about the programme and indicated 
that it may motivate them to receive help and change their behaviour with regard to substance use.
It is important not only to enforce drug-
driving laws but also to counsel and, when 
appropriate, treat drivers found to be 
impaired by drugs – especially those who 
are repeat offenders or those with drug-use 
disorders (Box 6). 
Counselling and treatment 
Box 7
Public health sector role
• Support and provide preventive interventions, counselling and, when appropriate, treatment for drivers found to be impaired 
by drugs – especially those who are repeat offenders or who have drug-use disorders. Applied programmes should be 
evaluated regularly for their effectiveness on traffic safety.
• In close cooperation with the road safety sector, participate in activities to raise awareness about drug-driving injury and 
other health risks, as well as evidence-based preventive interventions on drug use and road safety addressing the general 
public, policy-makers, drivers (especially young drivers), people using drugs, patients and health-care professionals.
• Conduct research and disseminate information on, for instance, the prevalence of drug use among drivers and the 
effectiveness of implemented measures.
• Provide guidance on the use and effects of prescription drugs on fitness to drive. For instance, risk communication can be 
based on a graded warning system with pictograms for medicines that impair driving. Key actors to provide this information 
to the patients are prescribing physicians and dispensing pharmacists.
• Ensure multisectoral collaboration with involvement of law enforcement officers and legislators. Recommendations for 
national activities regarding enforcement, education or campaigns should take into account country-specific characteristics 
of the problem.
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Suggestions for the future
Countries are at different stages of 
establishing and enforcing drug-driving 
laws. Reasonable progress is being made 
on drug-driving research, legislation and 
enforcement to support countries in this 
area. Available information shows that the 
use of psychoactive drugs increases risks for 
road traffic crashes and injuries. In summary, 
priorities and options for further action 
include:
• Determining prevalence of drivers’ drug 
use and drug-impaired driving, as well 
as the number of drug-impaired road 
traffic injuries and deaths. Additional data 
collection and research in this area are 
needed, particularly in low- and middle-
income countries. To clarify the magnitude 
of the risk of traffic injuries and crashes, 
studies are needed in order to generate 
and effectively communicate information 
on the prevalence of drug use and impaired 
driving among drivers in these countries. 
• Developing and establishing thresholds 
drug-driving laws and regulations. For 
“per se laws” it is critical to determine 
appropriate drug thresholds in blood and/
or saliva. For many drugs the specific 
relationship between concentration, 
impairment and the risk of a crash 
still needs more research. Ideally, an 
international working group could be 
constituted to review experiences in 
different countries and provide guidance 
on priorities for international collaboration 
in this area.
• Integrating drug-driving policies with 
drug policy frameworks oriented to public 
health. Drug-driving laws and programmes 
should be integrated into the overall drug 
policy frameworks. A similar approach has 
been used in drink-driving laws, which have 
been integrated into overall alcohol policies. 
Successful implementation of integrated 
policies and programmes requires effective 
multisectoral collaboration with the 
involvement of different sectors such as 
transport, police, health, drug control and 
education. Box 7 outlines the role of the 
public health sector. 
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